Europe Synthetic Hormones Market to Grow with a CAGR of 7.73% through 2030
Rising demand for fertility treatments and
advancements in hormone therapy is expected to drive the Europe Synthetic
Hormones Market growth in the forecast period, 2026-2030.
According to TechSci Research report, “Europe Synthetic
Hormones Market By Country, Competition, Forecast and Opportunities, 2030”,
the Europe Synthetic Hormones Market stood at USD 5.26 Billion in 2024 and is expected
to reach USD 8.24 Billion by 2030 with a CAGR of 7.73% during the forecast
period.
The Europe Synthetic Hormones Market is
experiencing significant growth, driven by a combination of demographic trends,
medical advancements, and evolving healthcare needs. The aging population in
Europe, coupled with an increasing awareness of hormonal health, is fostering a
rising demand for hormone-based treatments. With conditions such as menopause,
thyroid disorders, infertility, and growth hormone deficiencies becoming more
prevalent, synthetic hormones are playing an essential role in managing these health
concerns. Hormone Replacement Therapy (HRT), primarily using synthetic estrogen
and progesterone, remains one of the most widely utilized forms of treatment
for menopausal women, helping to alleviate symptoms such as hot flashes, mood
swings, and bone loss. The growing number of women entering menopause, combined
with longer life expectancies, is propelling the demand for synthetic hormone
therapies across Europe.
In addition to menopause, fertility
treatments represent a significant segment of the synthetic hormones market in
Europe. Synthetic hormones, including gonadotropins, progesterone, and
estrogen, are frequently used in assisted reproductive technologies (ART) like
in vitro fertilization (IVF) to support embryo development and pregnancy. With
increasing infertility rates and lifestyle changes contributing to delayed
pregnancies, the demand for fertility-related hormone treatments is expected to
grow. The rise of polycystic ovary syndrome (PCOS) and endometriosis, which
often lead to hormonal imbalances, is driving the demand for synthetic hormone
therapies, particularly among younger women.
The growth of the growth hormone
deficiency market in Europe also plays a role in shaping the synthetic hormones
landscape. Synthetic growth hormones are used to treat children and adults with
growth hormone deficiencies, promoting proper growth and development. Advances
in growth hormone treatments, such as the use of long-acting formulations, have
made it easier for patients to manage their condition with fewer injections,
improving adherence rates and enhancing treatment outcomes.
Another key factor driving the synthetic
hormones market in Europe is the increasing focus on women's health. There is a
growing recognition of the importance of addressing women’s hormonal health
issues, including menopause, fertility, and polycystic ovary syndrome (PCOS).
As healthcare systems evolve to place more emphasis on personalized medicine,
synthetic hormones are being tailored to meet individual needs, offering more
effective and safer treatments for women of all ages. Hormonal therapies are not
only used for menopause management but also for improving fertility and
managing other reproductive health conditions, further boosting the demand for
synthetic hormones.
In the male hormone therapy segment,
synthetic hormones like testosterone are gaining traction, particularly in the
treatment of male hypogonadism. As awareness of testosterone deficiency in
aging men grows, the demand for testosterone replacement therapy (TRT) is
expected to rise. Synthetic testosterone is used to restore normal levels in
men with low testosterone, improving symptoms such as fatigue, reduced libido,
and muscle weakness. The growing acceptance of hormone therapy for men is a
relatively recent trend, but it is gaining popularity across Europe, adding
another layer of growth to the synthetic hormones market.
The market for synthetic hormones is
also being influenced by technological advancements in drug delivery methods.
Newer formulations of hormone therapies, such as transdermal patches, gels, and
implants, are offering more convenient and effective ways of administering
hormones. These delivery systems not only improve patient compliance but also
reduce the risk of side effects associated with oral hormone therapy,
contributing to their increasing adoption. Advances in bioidentical hormones,
which are chemically identical to those produced by the human body, are gaining
popularity in hormone replacement therapy. These innovations are making
synthetic hormone therapies more effective, safer, and appealing to patients,
especially those seeking a more natural approach to hormone treatment.
Regulatory support from agencies like
the European Medicines Agency (EMA) is also playing a crucial role in the
growth of the synthetic hormones market. Regulatory bodies are ensuring the
safety and efficacy of synthetic hormone treatments through stringent approval
processes, which fosters consumer trust in these therapies. In turn, this has
facilitated the introduction of new hormone therapies to the market, as
pharmaceutical companies invest in research and development to create more
effective solutions. The regulatory environment is also conducive to the growth
of both established pharmaceutical giants and new entrants, further
intensifying competition and innovation in the market. While the market for
synthetic hormones in Europe is expanding, it is not without challenges.
Concerns over the side effects of synthetic hormones, particularly in relation
to hormone replacement therapy (HRT), have led to some hesitancy among patients
and healthcare providers. Studies have linked long-term use of HRT to an increased
risk of conditions such as breast cancer, blood clots, and stroke, which has
led to public debates and regulatory scrutiny. However, newer formulations and
personalized treatment plans are addressing some of these concerns, making
hormone therapies safer and more acceptable to patients.
Browse over XX market data Figures spread
through XX Pages and an in-depth TOC on " Europe Synthetic Hormones Market”
The Europe Synthetic Hormones Market is segmented into
product type, route of administration, application, end user, country
distribution, and company.
Based on end user, hospital pharmacies currently
dominate the market. Hospital pharmacies are a key point of access for patients
requiring hormone replacement therapy (HRT) and other synthetic hormone
treatments, especially for complex and critical conditions like hormone-related
cancers, thyroid dysfunctions, and fertility issues. These pharmacies are
typically well-equipped to handle the specialized needs of patients undergoing
synthetic hormone treatments, offering both prescription and personalized care.
In many cases, patients are initially diagnosed and treated within hospital
settings where they receive more comprehensive care and specialized hormone
therapies.
The role of hospital pharmacies is particularly
prominent in treating conditions that require close monitoring, such as growth
hormone deficiency, menopause, and thyroid disorders. For example, growth
hormone therapy often requires precise dosages and regular follow-ups, making
hospital pharmacies a preferred point of distribution due to their ability to
offer more tailored prescriptions. Similarly, when it comes to fertility
treatments involving synthetic hormones like gonadotropins, progesterone, and estrogen,
hospital pharmacies often serve as the primary provider, as fertility
treatments often require careful medical supervision and specialized
formulations. Hospital pharmacies provide access to hormone therapies for women
experiencing menopause, a condition that often requires ongoing treatment and
monitoring, thus fostering continued reliance on hospital settings.
Based on country, United Kingdom stands as the
second-largest player in the synthetic hormones market. While Germany holds the
dominant position in the European market, the United Kingdom's advanced
healthcare infrastructure, significant pharmaceutical industry, and strong
focus on women's health make it a major contributor to the growth of the
synthetic hormones sector. One of the key factors driving the dominance of the
United Kingdom in the synthetic hormones market is its well-established
healthcare system. The National Health Service (NHS) plays a crucial role in
providing access to hormone therapies, particularly hormone replacement therapy
(HRT), which is widely prescribed to women experiencing menopause. With an
aging population, the demand for HRT in the UK has been steadily increasing.
Menopause-related conditions such as hot flashes, mood swings, and bone density
loss are commonly treated with synthetic hormones like estrogen and
progesterone, contributing to the strong demand for these products.
The UK also has a high prevalence of thyroid
disorders, including hypothyroidism, which is typically managed through
synthetic thyroid hormones like levothyroxine. As thyroid dysfunction becomes
more prevalent among the aging population, the demand for synthetic hormone
therapies in the UK continues to rise. The growing awareness of conditions such
as polycystic ovary syndrome (PCOS) and infertility, which often require
hormonal treatments, has contributed to an increasing demand for synthetic
hormones, particularly in the reproductive health sector.
Major companies operating in Europe Synthetic Hormones
Market are:
- Ferring Hungary Ltd
- Novo Nordisk A/S
- Ipsen Biopharm Ltd
- Novartis AG
- Perrigo Company plc
- Sanofi S.A.
- Pfizer Holdings Netherlands B.V.
- Lupin Healthcare Ltd
- GSK plc
- Boehringer Ingelheim International
GmbH
Download Free Sample Report
Customers can also request for 10%
free customization on this report
“The future of the Europe Synthetic Hormones Market is
poised for robust growth, driven by an aging population, increasing prevalence
of hormonal disorders, and advancements in hormone therapies. Rising awareness
of hormone-related health issues, particularly in women's health, fertility
treatments, and thyroid conditions, is expected to further fuel demand.
Technological innovations in hormone delivery systems, such as transdermal
patches and bioidentical hormones, will enhance patient compliance and broaden
the market. Regulatory support and the ongoing development of personalized
hormone therapies will contribute to market expansion. As healthcare systems
prioritize affordable and effective treatments, the market for synthetic
hormones will continue to grow, with a notable focus on improving safety and
efficacy, paving the way for more widespread adoption and long-term market
stability.” said Mr. Karan Chechi, Research Director, TechSci Research, a
research-based management consulting firm.
“Europe Synthetic Hormones Market By Product Type (Steroid Hormones, Peptide Hormones, and Others), By Route of Administration (Subcutaneous, Oral, Intravenous/Intramuscular, and Others), By Application (Diabetes, Growth Hormone Deficiency, Contraception, Male Hypogonadism, Menopause, and Others), By End User (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), By Country, Competition, Forecast and Opportunities, 2020-2030F”, has evaluated the future growth potential of Europe
Synthetic Hormones Market and provides statistics & information on market
size, structure and future market growth. The report intends to provide
cutting-edge market intelligence and help decision makers take sound investment
decisions. Besides, the report also identifies and analyzes the emerging trends
along with essential drivers, challenges, and opportunities in Europe Synthetic
Hormones Market.
Contact
TechSci
Research LLC
420
Lexington Avenue, Suite 300,
New
York, United States- 10170
Tel: +1-332-258-6602
Email: [email protected]
Website: www.techsciresearch.com